Home » Topics » Regulatory » EMA

EMA
RSS

Cynapsus Therapeutics reaches agreement with the EMA for APL-130277 development

July 20, 2016

The EMA classifies AXAL as advanced therapy medicinal product

July 19, 2016

Cladribine tablet MAA accepted for review by EMA

July 18, 2016

EMA accepts for review MAA for adalimumab biosimilar SB-5

July 18, 2016

EMA committee recommends orphan drug designation for Akari's Coversin

July 13, 2016

EMA's review of conditional MAA for masitinib to follow standard timeline

July 5, 2016

EMA grants an expansion to orphan drug designation for ATIR-101

July 5, 2016

EMA committee recommends granting orphan drug designation to Vicore's C-21 in IPF

June 29, 2016

EMA recommends approval of Keytruda for advanced NSCLC

June 28, 2016

Puma submits MAA to the EMA for neratinib

June 28, 2016

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...